In adults, chronic congestive heart failure and systemic venous engorgement produce a spectrum of histologic and functional abnormalities in the liver, ranging from dilation of sinusoids with centrilobular necrosis to replacement of centrilobular hepatocytes with fibrous tissue and cirrhosis (29). Cardiac cirrhosis refers to the irreversible, end-stage phase of hepatic damage as a result of long-standing hepatic venous congestion from cardiac failure. In an autopsy study of 605 adults who died with chronic cardiac decompensation, 10% were noted to have histologic changes in the liver consistent with cardiac cirrhosis (30).
There is little information available regarding the long-term consequences of chronic hepatic congestion in children. Matsuda et al. (31) and Jenkins et al. (32) described a high incidence of acute liver dysfunction after the Fontan procedure, caused predominantly by low cardiac output, which did not correlate with the presence of abnormal standard liver blood tests obtained approximately 1 year after surgery. Moreover, serum aminotransferase levels were rarely elevated during long-term follow-up evaluation after the Fontan procedure (13,14). However, factors V (14) and VII (13) were low in 24% to 43% of patients during long-term follow-up evaluation after the Fontan procedure. Stanton et al. (33) described a patient who died suddenly 21 months after surgery, presumably from an arrhythmic event, who was found to have histologic evidence of cirrhosis. Lemmer et al. (11) reported a 13-year-old patient who developed cirrhosis 5 years after performance of a modified Fontan procedure for tricuspid atresia. Despite the concern for the potential deleterious consequences of the high central venous pressure on the liver, no study has examined the effect on quantitative tests of hepatic function in this clinical setting. It is important to define the scope of this problem for the following reasons. The indications for the Fontan procedure as corrective surgery have expanded beyond tricuspid atresia to include an increasing number of complex congenital cardiac defects. In addition, the operation is now being performed at an earlier age. Thus, there may be an increasing number of children who are at risk for the development of liver disease from chronically elevated systemic venous pressure. Orthotopic cardiac transplantation is now an option for patients who have undergone the Fontan procedure who experience late complications, or, in some cases, as an alternative treatment. Because cardiac transplantation risk is greatly increased if cirrhosis is established, cirrhosis is considered a relative contraindication to orthotopic cardiac transplantation at some centers. Liver biopsy in the setting of high right-sided cardiac pressures may carry an increased risk of bleeding from the higher pressures in the hepatic vein and the frequently associated coagulopathy. In addition, transjugular liver biopsy is usually precluded by the post-Fontan anatomy. Thus, it would be optimal to determine objective, noninvasive criteria that precede the development of cirrhosis so that intervention with cardiac transplantation could be offered to prevent further hepatic injury.
Liver biopsy is the most accurate current means of quantifying hepatic fibrosis. In this study, liver biopsies were only performed for clinical indications (primarily evaluation for orthotopic cardiac transplantation). Ideally, we would have preferred to have liver histology for all patients; however, the potential increased risk of bleeding and lack of access for transjugular liver biopsy precluded biopsy for research purposes alone on ethical grounds.
Doppler ultrasound evaluation of portal and splenic venous blood flow did not demonstrate reduced flow, suggesting that the effect of hepatic injury after the Fontan procedure is likely a decrease of hepatocyte mass. Although there was a trend to a larger left portal vein diameter in subjects with clinical liver disease, left portal vein diameter did not appear to be as useful a discriminant function as PT or GEC. The temporally related increase of PT in conjunction with the decrease in GEC suggest that hepatocyte loss of function may be the earliest hepatic abnormality that develops within 5 years of the Fontan procedure.
In conclusion, routine biochemical indices of hepatic injury may underestimate the extent of congestive hepatopathy and hepatic fibrosis after the Fontan procedure. In contrast, our data suggest that PT and GEC may be useful markers of hepatic dysfunction and fibrosis in these patients. Sequential determination of PT may be a useful part of the routine monitoring after the Fontan procedure. Further, prospective investigation of serial galactose clearance testing will be necessary to determine if this test is a useful predictor of progressive hepatic dysfunction and fibrosis after the Fontan procedure (34).
F, Baudet E. Surgical repair of tricuspid atresia. Thorax 1971; 26:240–8.
2. Castaneda AR. From Glenn to Fontan
, a continuing evolution. Circulation 1992; 86(suppl II):II-80–3.
3. Dick M, Fyler DC, Nadas AS. Tricuspid atresia: clinical course in 101 patients. Am J Cardiol 1975; 36:327–37.
4. Mayer JEJ, Bridges ND, Lock JE, et al. Factors associated with marked reduction in mortality for Fontan
operations in patients with single ventricle. J Thorac Cardiovasc Surg 1992; 103:444–51.
5. Mair DD, Rice MJ, Hagler DJ, et al. Outcome of the Fontan
procedure in patients with tricuspid atresia. Circulation 1985; 72:II88–92.
6. Driscoll DJ, Offord KP, Feldt RH, et al. Five- to fifteen-year follow-up after Fontan
operation. Circulation 1992; 85:469–96.
7. Sanders SP, Wright GB, Keane JF, et al. Clinical and hemodynamic results of the Fontan
operation for tricuspid atresia. Am J Cardiol 1982; 49:1733–40.
8. Mair DD, Hagler DJ, Puga FJ, et al. Fontan
operation in 176 patients with tricuspid atresia. Results and a proposed new index for patient selection. Circulation 1990; 82:IV164–9.
9. Mair DD, Hagler DJ, Julsrud PR, et al. Early and late results of the modified Fontan
procedure for double inlet left ventricle: the Mayo Clinic experience. J Am Coll Cardiol 1991; 18:1729–32.
10. Cohen AJ, Cleveland DC, J D, et al. Results of the Fontan
procedure for patients with univentricular heart. Ann Thorac Surg 1991; 52:1266–70.
11. Lemmer JH, Coran AG, Behrendt DM, et al. Liver fibrosis (cardiac cirrhosis
) five years after modified Fontan
operation for tricuspid atresia. J Thorac Cardiovasc Surg 1983; 86:757–60.
12. Behrendt DM, Rosentahl A. Cardiovascular status after repair by Fontan
procedure. Ann Thorac Surg 1980; 29:322–30.
13. Cromme-Dijkhuis AH, Hess J, Hahlen K, et al. Specific sequelae after Fontan
operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders. J Thorac Cardiovasc Surg 1993; 106:1126–32.
14. Kaulitz R, Luhmer I, Bergmann F, et al. Sequelae after modified Fontan
operation: postoperative haemodynamic data and organ function. Heart 1997; 78:154–9.
15. Sherlock S. The liver in circulatory failure. In: Schiff L, Schiff ER, eds. Diseases of the Liver.
Vol. 2. Philadelphia: JB Lippincott; 1993:1431–7.
16. Narkewicz MR, Smith D, Gregory C, et al. Effect of ursodeoxycholic acid therapy on hepatic function
in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998; 26:49–55.
17. Fletcher SE, Case CL, Fyfe DA, et al. Clinical spectrum of venous thrombi in the Fontan
patient. Am J Cardiol 1991; 68:1721–2.
18. Dobell AR, Trusler GA, Smallhorn JF, et al. Atrial thrombi after the Fontan
operation. Ann Thorac Surg 1986; 42:664–7.
19. Cromme-Dijkhuis AH, Henkens CM, Bijleveld CM, et al. Coagulation factor abnormalities as possible thrombotic risk factors after Fontan
operations. Lancet 1990; 336:1087–90.
20. Peters NS, Somerville J. Arrhythmias after the Fontan
procedure. Br Heart J 1992; 68:199–204.
21. Hess J, Kruizinga K, Bijleveld CM, et al. Protein-losing enteropathy after Fontan
operation. J Thorac Cardiovasc Surg 1984; 88:606–9.
22. Rothman A, Snyder J. Protein-losing enteropathy following the Fontan
operation: resolution with prednisone therapy. Am Heart J 1991; 121:618–9.
23. Rychik J, Piccoli DA, Barber G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan
procedure. Am J Cardiol 1991; 68:819–21.
24. Hanseus K, Bjorkhem G, Lundstrom NR. Dimensions of cardiac chambers and great vessels by cross-sectional echocardiography in infants and children. Pediatr Cardiol 1988; 9:7–15.
25. Hjelm M, de Verdier CH. Colorimetric method with galactose oxidase. In: Bergmeyer H, Bergmeyer J, Grabl M, eds. Methods of Enzymatic Analysis.
Vol. 6. Deerfield Beach, FL: Verlag Chemie, 1984:281–8.
26. Lindskov J. The quantitative liver function as measured by the galactose elimination capacity. II. Prognostic value and changes during disease in patients with cirrhosis. Acta Med Scand 1982; 212:303–8.
27. Vocke AK, Kardorff R, Ehrich JH. Sonographic measurements of the portal vein and its intrahepatic branches in children. Eur J Ultrasound 1998; 7:121–7.
28. Wanek EA, Horgan JG, Karrer FM, et al. Portal venous velocity in biliary atresia. J Pediatr Surg 1990; 25:146–8.
29. Dunn GD, Hayes P, Breen KJ, et al. The liver in congestive heart failure: a review. Am J Med Sci 1973; 265:174–89.
30. Kotin P, Hall E. “Cardiac” or congestive cirrhosis of liver. Am J Pathol 1951; 27:561–71.
31. Matsuda H, Covino E, Hirose H, et al. Acute liver dysfunction after modified Fontan
operation for complex cardiac lesions. Analysis of the contributing factors and its relation to the early prognosis. J Thorac Cardiovasc Surg 1988; 96:219–26.
32. Jenkins JG, Lynn AM, Wood AE, et al. Acute hepatic failure following cardiac operation in children. J Thorac Cardiovasc Surg 1982; 84:865–71.
33. Stanton RE, Lurie PR, Lindesmith GG, et al. The Fontan
procedure for tricuspid atresia. Circulation 1981; 64:II140–6.
34. Zaramella MG, Vallini R, Tiribelli C. Estimation of the hepatic blood “flow” by galactose plasma clearance in patients with liver disease. Liver 1985; 5:129–33.